HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Sue O'Dorisio Selected Research

Somatostatin Receptors (Somatostatin Receptor)

10/2021Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
1/2020Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors.
11/201890Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.
12/2013Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
10/2010Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.
12/2008Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children.
4/2008Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors.
3/2008Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies.
5/2004Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging.
11/2002Expression of somatostatin receptors 1 and 2 in human choroid plexus and arachnoid granulations: implications for idiopathic intracranial hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Sue O'Dorisio Research Topics

Disease

27Neoplasms (Cancer)
04/2022 - 11/2002
16Neuroendocrine Tumors (Neuroendocrine Tumor)
12/2021 - 04/2006
9Neuroblastoma
10/2021 - 11/2002
5Primitive Neuroectodermal Tumors (PNET)
09/2014 - 05/2004
5Medulloblastoma
10/2013 - 11/2003
3Carcinoid Tumor (Carcinoid)
10/2021 - 04/2008
3Neoplasm Metastasis (Metastasis)
10/2021 - 12/2013
2Neuroendocrine Carcinoma
04/2022 - 10/2021
2Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/2017 - 01/2016
2Cicatrix (Scar)
12/2008 - 03/2008
1Pheochromocytoma
10/2021
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2021
1Disease Progression
01/2019
1Paraganglioma (Paragangliomas)
10/2010
1Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis)
10/2010
1Brain Neoplasms (Brain Tumor)
10/2010
1Astrocytoma (Pilocytic Astrocytoma)
12/2008
1Thyroid Nodule (Nodule, Thyroid)
09/2008
1Thyroid Neoplasms (Thyroid Cancer)
09/2008
1Islet Cell Adenoma (Islet Cell Tumors)
04/2008
1Necrosis
03/2008
1Carcinogenesis
12/2006
1Typical Teratoid Rhabdoid Tumor
03/2005
1Wilms Tumor (Wilm's Tumor)
01/2005
1Ganglion Cysts (Ganglion)
10/2004
1Blindness (Hysterical Blindness)
10/2004
1Glioblastoma (Glioblastoma Multiforme)
05/2004
1Ependymoma
05/2004
1Rhabdomyosarcoma
05/2004
1Triploidy
11/2002
1Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
11/2002

Drug/Important Bio-Agent (IBA)

10Somatostatin Receptors (Somatostatin Receptor)IBA
10/2021 - 11/2002
6Octreotide (Sandostatin)FDA LinkGeneric
04/2022 - 11/2002
6Peptide Receptors (Peptide Receptor)IBA
04/2022 - 10/2010
5Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
04/2022 - 11/2002
5Ga(III)-DOTATOCIBA
10/2021 - 08/2013
4Radioisotopes (Radionuclides)IBA
12/2021 - 10/2010
4DOTA-Tyr(3)- 90Y-octreotideIBA
01/2021 - 04/2006
43-Iodobenzylguanidine (Iobenguane)IBA
01/2019 - 01/2005
3Edotreotide (SMT 487)IBA
01/2020 - 04/2006
3somatostatin receptor 2IBA
01/2017 - 05/2004
3LigandsIBA
01/2016 - 01/2005
3RNA (Ribonucleic Acid)IBA
08/2014 - 12/2012
3Messenger RNA (mRNA)IBA
12/2013 - 01/2005
2Chromogranin AIBA
04/2022 - 09/2014
2NeuropeptidesIBA
01/2020 - 11/2002
2Peptides (Polypeptides)IBA
01/2020 - 12/2008
2Type I Vasoactive Intestinal Polypeptide ReceptorsIBA
01/2017 - 01/2016
2pancreastatinIBA
09/2014 - 07/2010
2Proteins (Proteins, Gene)FDA Link
10/2013 - 09/2008
1SynaptophysinIBA
04/2022
1Norepinephrine (Noradrenaline)FDA LinkGeneric
10/2021
1Histone Deacetylases (Histone Deacetylase)IBA
10/2021
1Histone Deacetylase InhibitorsIBA
10/2021
1VorinostatFDA Link
10/2021
1lanreotide (Somatuline)FDA Link
01/2020
1Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA
01/2016
1Neurokinin AIBA
09/2014
1Serotonin (5 Hydroxytryptamine)IBA
09/2014
1Pharmaceutical PreparationsIBA
08/2014
1gastric inhibitory polypeptide receptorIBA
12/2013
1Oxytocin Receptors (Oxytocin Receptor)IBA
12/2013
1Membrane Proteins (Integral Membrane Proteins)IBA
12/2013
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
10/2013
1Gallium-68IBA
08/2013
1Biological ProductsIBA
08/2013
1Biomarkers (Surrogate Marker)IBA
01/2011
1CatecholaminesIBA
08/2010
1AntibodiesIBA
07/2010
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
06/2010
1AntioxidantsIBA
06/2010
1Sulfhydryl Compounds (Thiols)IBA
06/2010
1Superoxide DismutaseIBA
06/2010
1Cysteine (L-Cysteine)FDA Link
06/2010
1CatalaseIBA
06/2010
1Glucose (Dextrose)FDA LinkGeneric
06/2010
1Deoxyglucose (2 Deoxy D glucose)IBA
06/2010
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2010
1pentetreotide (OctreoScan)FDA Link
12/2008
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
09/2008
1Caspase 8 (Caspase-8)IBA
01/2005
1GTP-Binding Proteins (G-Protein)IBA
01/2005
1EnzymesIBA
01/2005
1SurvivinIBA
01/2005
1AcidsIBA
01/2005
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2004
1Retinaldehyde (Retinal)IBA
10/2004
1Retinal Pigments (Pigments, Visual)IBA
10/2004
1Insulin-Like Growth Factor I (IGF-1)IBA
10/2004
1LuciferasesIBA
11/2003
1Adenylyl Cyclases (Adenylyl Cyclase)IBA
11/2002
1DNA (Deoxyribonucleic Acid)IBA
11/2002
1Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)IBA
11/2002

Therapy/Procedure

14Therapeutics
04/2022 - 01/2005
5Radiotherapy
01/2020 - 03/2005
2Drug Therapy (Chemotherapy)
01/2020 - 01/2019
1Biological Therapy
01/2020
1Anesthesia
08/2010
1Operative Surgical Procedures
08/2010